BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines. Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short,” the article reads. “Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases. Its lead candidate, OT-101, is a pioneering anti-TGF-β RNA therapeutic that has demonstrated single-agent activity in relapsed and refractory cancers. OT-101 also exhibits activity against SARS-CoV-2, underscoring its versatile potential. Importantly, OT-101 has received rare pediatric designations for aggressive diseases such as diffuse intrinsic pontine glioma (‘DIPG’), melanoma (via CA4P) and acute myeloid leukemia (via OXi4503), highlighting the company’s focus on underserved populations.”

To view the full article, visit https://ibn.fm/NC4Xa

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN